Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TLB001
- Development stage
- Phase 1
- Lead developer
- TianLi Biotech
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
TLB001 is a proprietary small molecule inhibitor of casein kinase 1 delta and epsilon (CK1 δ/ε) being developed by TianLi Biotech, a joint venture between the University of Melbourne and Beijing No.1 Biotechnology Group. The drug is designed to treat idiopathic pulmonary fibrosis (IPF) by modulating downstream TGF-β signaling pathways, thereby suppressing the fibrotic process. TLB001 is formulated as an inhaled aerosol solution for direct delivery to the lungs, which aims to maximize local therapeutic efficacy while minimizing systemic adverse effects often seen with oral anti-fibrotic treatments. In August 2024, TLB001 advanced into Phase I clinical trials in Australia to assess its safety, tolerability, and pharmacokinetics in healthy volunteers.
02
Targets
CSNK1D (Casein kinase I delta)CSNK1E (Casein kinase I isoform epsilon)TGFB (GARP–latent transforming growth factor beta 1 complex)
Beyond the preview
Go deeper on TLB001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TLB001.